{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:49:20Z","timestamp":1790470160678,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000849","name":"National Centre for the Replacement, Refinement and Reduction of Animals in Research","doi-asserted-by":"publisher","award":["NC\/K500331\/1"],"award-info":[{"award-number":["NC\/K500331\/1"]}],"id":[{"id":"10.13039\/501100000849","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000849","name":"National Centre for the Replacement, Refinement and Reduction of Animals in Research","doi-asserted-by":"publisher","award":["NC\/K500331\/1"],"award-info":[{"award-number":["NC\/K500331\/1"]}],"id":[{"id":"10.13039\/501100000849","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000294","name":"Medical Research Scotland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000294","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009323","name":"Animal Free Research UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009323","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Leukaemic stem cell (LSC) persistence remains a major obstacle to curing chronic myeloid leukaemia (CML). The bone morphogenic protein (BMP) pathway is deregulated in CML, with altered expression and response to the BMP ligands shown to impact on LSC expansion and behaviour. In this study, we determined whether alterations in the BMP pathway gene signature had any predictive value for therapeutic response by profiling 60 CML samples at diagnosis from the UK SPIRIT2 trial and correlating the data to treatment response using the 18-month follow-up data. There was significant deregulation of several genes involved in the BMP pathway with\n                    <jats:italic>ACV1C, INHBA, SMAD7, SNAIL1<\/jats:italic>\n                    and\n                    <jats:italic>SMURF2<\/jats:italic>\n                    showing differential expression in relation to response. Therapeutic targeting of CML cells using BMP receptor inhibitors, in combination with tyrosine kinase inhibitor (TKI), indicate a synergistic mode of action. Furthermore, dual treatment resulted in altered cell cycle gene transcription and irreversible cell cycle arrest, along with increased apoptosis compared to single agents. Targeting CML CD34\n                    <jats:sup>+<\/jats:sup>\n                    cells with BMP receptor inhibitors resulted in fewer cell divisions, reduced numbers of CD34\n                    <jats:sup>+<\/jats:sup>\n                    cells and colony formation when compared to normal donor CD34\n                    <jats:sup>+<\/jats:sup>\n                    cells, both in the presence and absence of BMP4. In an induced pluripotent stem cell (iPSC) model generated from CD34\n                    <jats:sup>+<\/jats:sup>\n                    hematopoietic cells, we demonstrate altered cell cycle profiles and dynamics of ALK expression in CML-iPSCs in the presence and absence of BMP4 stimulation, when compared to normal iPSC. Moreover, dual targeting with TKI and BMP inhibitor prevented the self-renewal of CML-iPSC and increased meso-endodermal differentiation. These findings indicate that transformed stem cells may be more reliant on BMP signalling than normal stem cells. These changes offer a therapeutic window in CML, with intervention using BMP inhibitors in combination with TKI having the potential to target LSC self-renewal and improve long-term outcome for patients.\n                  <\/jats:p>","DOI":"10.1038\/s41419-018-0905-2","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T05:22:47Z","timestamp":1536643367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal"],"prefix":"10.1038","volume":"9","author":[{"given":"Parto","family":"Toofan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-4191","authenticated-orcid":false,"given":"Heather","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhairi","family":"Copland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Wheadon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"905_CR1","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","volume":"94","author":"T Holyoake","year":"1999","unstructured":"Holyoake, T., Jiang, X., Eaves, C. & Eaves, A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94, 2056\u20132064 (1999).","journal-title":"Blood"},{"key":"905_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319\u2013325 (2002).","journal-title":"Blood"},{"key":"905_CR3","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland, M. et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107, 4532\u20134539 (2006).","journal-title":"Blood"},{"key":"905_CR4","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG Jorgensen","year":"2007","unstructured":"Jorgensen, H. G., Allan, E. K., Jordanides, N. E., Mountford, J. C. & Holyoake, T. L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+CML cells. Blood 109, 4016\u20134019 (2007).","journal-title":"Blood"},{"key":"905_CR5","doi-asserted-by":"crossref","unstructured":"Jamieson, C. H. Chronic myeloid leukemia stem cells. Hematol. Am. Soc. Hematol. Educ. Program 2008, 436\u2013442 (2008).","DOI":"10.1182\/asheducation-2008.1.436"},{"key":"905_CR6","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"JC Chomel","year":"2011","unstructured":"Chomel, J. C. et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 118, 3657\u20133660 (2011).","journal-title":"Blood"},{"key":"905_CR7","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu, S. et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118, 5565\u20135572 (2011).","journal-title":"Blood"},{"key":"905_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne, G. et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J. Clin. Oncol. 35, 298\u2013305 (2017).","journal-title":"J. Clin. Oncol."},{"key":"905_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea, D. et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129, 846\u2013854 (2017).","journal-title":"Blood"},{"key":"905_CR10","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.2174\/092986708786848541","volume":"15","author":"I Ischenko","year":"2008","unstructured":"Ischenko, I., Seeliger, H., Schaffer, M., Jauch, K. W. & Bruns, C. J. Cancer stem cells: how can we target them? Curr. Med. Chem. 15, 3171\u20133184 (2008).","journal-title":"Curr. Med. Chem."},{"key":"905_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/path.2793","volume":"223","author":"MR Alison","year":"2011","unstructured":"Alison, M. R., Lim, S. M. & Nicholson, L. J. Cancer stem cells: problems for therapy? J. Pathol. 223, 147\u2013161 (2011).","journal-title":"J. Pathol."},{"key":"905_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clml.2011.10.003","volume":"12","author":"T Al Baghdadi","year":"2012","unstructured":"Al Baghdadi, T., Abonour, R. & Boswell, H. S. Novel combination treatments targeting chronic myeloid leukemia stem cells. Clin. Lymphoma Myeloma Leuk. 12, 94\u2013105 (2012).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"905_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep25476","volume":"6","author":"DA Irvine","year":"2016","unstructured":"Irvine, D. A. et al. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci. Rep. 6, 25476 (2016).","journal-title":"Sci. Rep."},{"key":"905_CR14","doi-asserted-by":"publisher","first-page":"953982","DOI":"10.1155\/2013\/953982","volume":"2013","author":"F Nwajei","year":"2013","unstructured":"Nwajei, F. & Konopleva, M. The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv. Hematol. 2013, 953982 (2013).","journal-title":"Adv. Hematol."},{"key":"905_CR15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.18632\/oncotarget.990","volume":"4","author":"JM Gerber","year":"2013","unstructured":"Gerber, J. M. et al. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget 4, 715\u2013728 (2013).","journal-title":"Oncotarget"},{"key":"905_CR16","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1182\/blood-2013-05-501460","volume":"122","author":"B Laperrousaz","year":"2013","unstructured":"Laperrousaz, B. et al. Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. Blood 122, 3767\u20133777 (2013).","journal-title":"Blood"},{"key":"905_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1042\/BST20140037","volume":"42","author":"P Toofan","year":"2014","unstructured":"Toofan, P., Irvine, D., Hopcroft, L., Copland, M. & Wheadon, H. The role of the bone morphogenetic proteins in leukaemic stem cell persistence. Biochem. Soc. Trans. 42, 809\u2013815 (2014).","journal-title":"Biochem. Soc. Trans."},{"key":"905_CR18","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122, 872\u2013884 (2013).","journal-title":"Blood"},{"key":"905_CR19","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1182\/blood-2017-08-801019","volume":"130","author":"E Grockowiak","year":"2017","unstructured":"Grockowiak, E. et al. Immature CML cells implement a BMP autocrine loop to escape TKI treatment. Blood 130, 2860\u20132871 (2017).","journal-title":"Blood"},{"key":"905_CR20","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.biocel.2010.07.018","volume":"42","author":"JH Boergermann","year":"2010","unstructured":"Boergermann, J. H., Kopf, J., Yu, P. B. & Knaus, P. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int. J. Biochem. Cell Biol. 42, 1802\u20131807 (2010).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"905_CR21","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/nm.1888","volume":"14","author":"PB Yu","year":"2008","unstructured":"Yu, P. B. et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat. Med. 14, 1363\u20131369 (2008).","journal-title":"Nat. Med."},{"key":"905_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.bbagrm.2013.08.002","volume":"1829","author":"TC Lewis","year":"2013","unstructured":"Lewis, T. C. & Prywes, R. Serum regulation of Id1 expression by a BMP pathway and BMP responsive element. Biochim. Biophys. Acta 1829, 1147\u20131159 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"905_CR23","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1158\/0008-5472.CAN-05-1584","volume":"66","author":"M Nieborowska-Skorska","year":"2006","unstructured":"Nieborowska-Skorska, M. et al. Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region\/abelson tyrosine kinase-transformed leukemia cells. Cancer Res. 66, 4108\u20134116 (2006).","journal-title":"Cancer Res."},{"key":"905_CR24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/onc.2008.451","volume":"28","author":"JY Lee","year":"2009","unstructured":"Lee, J. Y. et al. Id-1 activates Akt-mediated Wnt signaling andp27(Kip1) phosphorylation through PTEN inhibition. Oncogene 28, 824\u2013831 (2009).","journal-title":"Oncogene"},{"key":"905_CR25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1535-6108(03)00141-7","volume":"3","author":"HA Sikder","year":"2003","unstructured":"Sikder, H. A., Devlin, M. K., Dunlap, S., Ryu, B. & Alani, R. M. Id proteins in cell growth and tumorigenesis. Cancer Cell 3, 525\u2013530 (2003).","journal-title":"Cancer Cell"},{"key":"905_CR26","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake, T. L. & Vetrie, D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129, 1595\u20131606 (2017).","journal-title":"Blood"},{"key":"905_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1210\/edrv.21.4.0403","volume":"21","author":"A Yamaguchi","year":"2000","unstructured":"Yamaguchi, A., Komori, T. & Suda, T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr. Rev. 21, 393\u2013411 (2000).","journal-title":"Endocr. Rev."},{"key":"905_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s002239900230","volume":"60","author":"D Chen","year":"1997","unstructured":"Chen, D. et al. Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif. Tissue Int. 60, 283\u2013290 (1997).","journal-title":"Calcif. Tissue Int."},{"key":"905_CR29","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.1038\/sj.onc.1208920","volume":"24","author":"J Larsson","year":"2005","unstructured":"Larsson, J. & Karlsson, S. The role of Smad signaling in hematopoiesis. Oncogene 24, 5676\u20135692 (2005).","journal-title":"Oncogene"},{"key":"905_CR30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nature02040","volume":"425","author":"LM Calvi","year":"2003","unstructured":"Calvi, L. M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841\u2013846 (2003).","journal-title":"Nature"},{"key":"905_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.tcb.2010.01.008","volume":"20","author":"DW Walsh","year":"2010","unstructured":"Walsh, D. W., Godson, C., Brazil, D. P. & Martin, F. Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol. 20, 244\u2013256 (2010).","journal-title":"Trends Cell Biol."},{"key":"905_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/jb\/mvp148","volume":"147","author":"K Miyazono","year":"2010","unstructured":"Miyazono, K., Kamiya, Y. & Morikawa, M. Bone morphogenetic protein receptors and signal transduction. J. Biochem. 147, 35\u201351 (2010).","journal-title":"J. Biochem."},{"key":"905_CR33","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1182\/blood-2009-11-254680","volume":"117","author":"E Cosset","year":"2011","unstructured":"Cosset, E. et al. Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood 117, 1673\u20131676 (2011).","journal-title":"Blood"},{"key":"905_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini, A. et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat. Med. 23, 692\u2013704 (2017).","journal-title":"Nat. Med."},{"key":"905_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature08734","volume":"463","author":"K Naka","year":"2010","unstructured":"Naka, K. et al. TGFb\u2013FOXO signalling maintains leukaemia initiating cells in chronic myeloid leukaemia. Nature 463, 676\u2013682 (2010).","journal-title":"Nature"},{"key":"905_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/leu.2016.34","volume":"30","author":"E Nievergall","year":"2016","unstructured":"Nievergall, E. et al. TGF-\u03b1 and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia 30, 1263\u20131272 (2016).","journal-title":"Leukemia"},{"key":"905_CR37","doi-asserted-by":"publisher","first-page":"15007","DOI":"10.1038\/npjbcancer.2015.7","volume":"1","author":"M Bashir","year":"2015","unstructured":"Bashir, M., Damineni, S., Mukherjee, G. & Kondaiah, P. Activin-A signaling promotes epithelial\u2013mesenchymal transition, invasion, and metastatic growth of breast cancer. NPJ Breast Can. 1, 15007 (2015).","journal-title":"NPJ Breast Can."},{"key":"905_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.canlet.2014.10.037","volume":"356","author":"Y Togashi","year":"2015","unstructured":"Togashi, Y. et al. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett. 356, 819\u2013827 (2015).","journal-title":"Cancer Lett."},{"key":"905_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/cancers7010070","volume":"7","author":"HA Loomans","year":"2015","unstructured":"Loomans, H. A. & Andl, C. D. Intertwining of activin A and TGF\u03b2 signaling: dual roles in cancer progression and cancer cell invasion. Cancers 7, 70\u201391 (2015).","journal-title":"Cancers"},{"key":"905_CR40","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/leu.2013.385","volume":"28","author":"R Silbermann","year":"2014","unstructured":"Silbermann, R. et al. Bone marrow monocyte-\/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia 28, 951\u2013954 (2014).","journal-title":"Leukemia"},{"key":"905_CR41","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","volume":"121","author":"B Zhang","year":"2013","unstructured":"Zhang, B. et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt\u2013\u03b2-catenin signaling. Blood 121, 1824\u20131838 (2013).","journal-title":"Blood"},{"key":"905_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1365-2141.1998.00564.x","volume":"100","author":"T Jonuleit","year":"1998","unstructured":"Jonuleit, T. et al. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br. J. Haematol. 100, 295\u2013303 (1998).","journal-title":"Br. J. Haematol."},{"key":"905_CR43","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1080\/15384101.2016.1160976","volume":"15","author":"D Moreno-Lorenzana","year":"2016","unstructured":"Moreno-Lorenzana, D. et al. CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI. Cell Cycle 15, 1276\u20131287 (2016).","journal-title":"Cell Cycle"},{"key":"905_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc2368","volume":"8","author":"M Savona","year":"2008","unstructured":"Savona, M. & Talpaz, M. Getting to the stem of chronic myeloid leukaemia. Nat. Rev. Cancer 8, 341\u2013350 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"905_CR45","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0962-8924(03)00147-8","volume":"13","author":"MB Ruzinova","year":"2003","unstructured":"Ruzinova, M. B. & Benezra, R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 13, 410\u2013418 (2003).","journal-title":"Trends Cell Biol."},{"key":"905_CR46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/08977190412331279890","volume":"22","author":"D Chen","year":"2004","unstructured":"Chen, D., Zhao, M. & Mundy, G. R. Bone morphogenetic proteins. Growth Factors 22, 233\u2013241 (2004).","journal-title":"Growth Factors"},{"key":"905_CR47","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.bcp.2013.01.004","volume":"85","author":"A Bandyopadhyay","year":"2013","unstructured":"Bandyopadhyay, A., Yadav, P. S. & Prashar, P. BMP signaling in development and diseases: a pharmacological perspective. Biochem. Pharmacol. 85, 857\u2013864 (2013).","journal-title":"Biochem. Pharmacol."},{"key":"905_CR48","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(03)00847-X","volume":"115","author":"QL Ying","year":"2003","unstructured":"Ying, Q.-L. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115, 281\u2013292 (2003).","journal-title":"Cell"},{"key":"905_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9040","volume":"6","author":"M Crisan","year":"2015","unstructured":"Crisan, M. et al. BMP signalling differentially regulates distinct haematopoietic stem cell types. Nat. Commun. 6, 8040 (2015).","journal-title":"Nat. Commun."},{"key":"905_CR50","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1182\/blood-2011-07-367441","volume":"119","author":"K Kumano","year":"2012","unstructured":"Kumano, K. et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 119, 6234\u20136242 (2012).","journal-title":"Blood"},{"key":"905_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1432-0436.2006.00083.x","volume":"74","author":"MT Ling","year":"2006","unstructured":"Ling, M. T., Wang, X., Zhang, X. & Wong, Y. C. The multiple roles of Id-1 in cancer progression. Differentiation 74, 481\u2013487 (2006).","journal-title":"Differentiation"},{"key":"905_CR52","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2007-07-103010","volume":"112","author":"WF Tam","year":"2008","unstructured":"Tam, W. F. et al. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood 112, 1981\u20131992 (2008).","journal-title":"Blood"},{"key":"905_CR53","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-07-6403","volume":"68","author":"O Gautschi","year":"2008","unstructured":"Gautschi, O. et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 68, 2250\u20132258 (2008).","journal-title":"Cancer Res."},{"key":"905_CR54","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.celrep.2016.06.092","volume":"16","author":"X Jin","year":"2016","unstructured":"Jin, X. et al. The ID1-CULLIN3 axis regulates intracellular SHH and WNT signaling in glioblastoma stem cells. Cell Rep. 16, 1629\u20131641 (2016).","journal-title":"Cell Rep."},{"key":"905_CR55","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.stem.2007.10.022","volume":"2","author":"C Lengerke","year":"2008","unstructured":"Lengerke, C. et al. BMP and Wnt specify hematopoietic fate by activation of the Cdx-Hox pathway. Cell Stem Cell 2, 72\u201382 (2008).","journal-title":"Cell Stem Cell"},{"key":"905_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1749-6632.2012.06625.x","volume":"1266","author":"C Lengerke","year":"2012","unstructured":"Lengerke, C. & Daley, G. Q. Caudal genes in blood development and leukemia. Ann. N. Y. Acad. Sci. 1266, 47\u201354 (2012).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"905_CR57","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/sj.leu.2404657","volume":"21","author":"A Sengupta","year":"2007","unstructured":"Sengupta, A. et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 21, 949\u2013955 (2007).","journal-title":"Leukemia"},{"key":"905_CR58","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1158\/1078-0432.CCR-07-0919","volume":"13","author":"G Strathdee","year":"2007","unstructured":"Strathdee, G. et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin. Cancer Res. 13, 5048\u20135055 (2007).","journal-title":"Clin. Cancer Res."},{"key":"905_CR59","doi-asserted-by":"publisher","first-page":"e62721","DOI":"10.1371\/journal.pone.0062721","volume":"8","author":"CE Sanvitale","year":"2013","unstructured":"Sanvitale, C. E. et al. A new class of small molecule inhibitor of BMP signaling. PLoS ONE 8, e62721 (2013).","journal-title":"PLoS ONE"},{"key":"905_CR60","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/19420862.2016.1158380","volume":"8","author":"S Calpe","year":"2016","unstructured":"Calpe, S., Correia, A. C., Sancho-Serra Mdel, C. & Krishnadath, K. K. Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors. Mabs 8, 678\u2013688 (2016).","journal-title":"Mabs"},{"key":"905_CR61","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1158\/1535-7163.MCT-13-0103-T","volume":"12","author":"H Mistry","year":"2013","unstructured":"Mistry, H. et al. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol. Cancer Ther. 12, 2651\u20132662 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"905_CR62","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-16-2692","volume":"23","author":"DS Das","year":"2017","unstructured":"Das, D. S. et al. Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells. Clin. Cancer Res. 23, 4280\u20134289 (2017).","journal-title":"Clin. Cancer Res."},{"key":"905_CR63","unstructured":"https:\/\/www.press.pfizer.com\/press-release\/pfizers-next-generation-alkros1-inhibitor-lorlatinib-granted-breakthrough-therapy-desi"},{"key":"905_CR64","unstructured":"https:\/\/www.openinnovation.astrazeneca.com\/saracatinib-azd0530.html"},{"key":"905_CR65","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol. Rev."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0905-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0905-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0905-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:10:54Z","timestamp":1671520254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0905-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-0905-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"5 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"927"}}